Dexcom beats profit estimates on strong demand for glucose monitors
Dexcom Launches Dexcom One+ Bringing Technology to More People
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
Dexcom Announces Upcoming Conference Presentation
Dexcom Reports Third Quarter 2023 Financial Results
The roster of college athletes at Dexcom U is growing as the blood sugar monitoring company recruits another 11 players for sponsorships.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call to review the company's second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.
Earlier this year, while speaking with Fierce Medtech at the annual J.P. Morgan Healthcare Conference, Dexcom CEO Kevin Sayer noted that the continuous glucose monitor maker had recently changed its mission statement—swapping “health” for “diabetes” in its aim of “Empowering people to take control of health.”
After collecting a long-awaited FDA clearance for the latest generation of its wearable continuous glucose monitor last December, Dexcom has offered a peek into the momentum behind its G7 diabetes sensor.
DexCom Comments on SVB Relationship